Skip to main content
Log in

Pharmacokinetic and Pharmacodynamic Interaction between Allopurinol and Probenecid in Healthy Subjects

  • Original Research Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Background and objective: Combination therapy with allopurinol and probenecid is used to treat tophaceous gout in patients who do not respond sufficiently to allopurinol alone. However, the potential interaction between these drugs has not been systematically investigated. The objective of this study was to investigate the pharmacokinetics and hypouricaemic effect of oxypurinol (the active metabolite of allopurinol) and probenecid when administered alone and in combination in healthy subjects.

Methods: An open-label, randomized, three-way crossover clinical trial was conducted in 12 healthy adults. Subjects were randomized to receive treatment for 7 days with allopurinol (150 mg twice daily), probenecid (500 mg twice daily) or combination therapy with both drugs, with a 7-day washout period between treatments. Venous blood samples were collected predose (at 0 hours) and 1, 2, 3, 4, 6, 8, 10 and 12 hours after dosage for determination of oxypurinol and/or probenecid concentrations. Plasma and urinary urate concentrations were determined on each study day and at the end of each washout period. Pharmacokinetic and pharmacodynamic parameters were analysed using two-way ANOVA.

Results: Coadministration of allopurinol and probenecid significantly reduced average steady-state plasma oxypurinol concentrations (mean ± SD: allopurinol alone 9.7 ± 2.1 mg/L vs combination 5.1 ± 1.0 mg/L, p < 0.001). Probenecid concentrations were unaffected. Plasma urate concentrations decreased (p < 0.01) during allopurinol therapy (0.16 ± 0.05 mmol/L), probenecid therapy (0.13 ± 0.02 mmol/L) and combination therapy (0.09 ± 0.02 mmol/L) compared with baseline (0.30 ± 0.05 mmol/L).

Conclusion: Coadministration of allopurinol and probenecid to healthy subjects had a greater hypouricaemic effect than either allopurinol or probenecid alone, despite a reduction in plasma oxypurinol concentrations when the drugs were taken concomitantly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Brewis I, Ellis R Scott. Single daily dose of allopurinol. Ann Rheum Dis 1975; 34: 256–9

    Article  PubMed  CAS  Google Scholar 

  2. Day RO, Miners J, Birkett D, et al. Allopurinol dosage selection: relationships between dose and plasma oxypurinol and urate concentrations and urinary urate excretion. Br J Clin Pharmcol 1988; 26: 423–8

    Article  CAS  Google Scholar 

  3. Elion GB, Kovensky A, Hitchings GH, et al. Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochemical Pharmacol 1966; 15: 863–80

    Article  CAS  Google Scholar 

  4. Day RO, Graham GG, Hicks M, et al. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet 2007; 46: 623–44

    Article  PubMed  CAS  Google Scholar 

  5. Walter-Sack I, de Vries JX, Ernst B, et al. Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients: therapeutic equivalence to allopurinol. J Rheumatol 1996; 23: 498–501

    PubMed  CAS  Google Scholar 

  6. Walter-Sack I, de Vries JX, Kreiner C, et al. Bioequivalence of allopurinol preparations: to be assessed by the parent drug or the active metabolite? Clin Investig 1993; 71: 240–6

    Article  PubMed  CAS  Google Scholar 

  7. Anzai N, Enomoto A, Endou H. Renal urate handling clinical relevance of recent advances. Curr Rheumatol Rep 2005; 7: 227–34

    Article  PubMed  CAS  Google Scholar 

  8. Robertson EE, Rankin GO. Human renal organic anion transporters: characteristics and contributions to drug and drug metabolite excretion. Pharmacol Ther 2006; 109: 399–412

    Article  PubMed  CAS  Google Scholar 

  9. Gutman AB. Uricosuric drugs, with special reference to probenecid and sulfinpyrazone. Adv Pharmacol 1966; 4: 91–142

    Article  PubMed  CAS  Google Scholar 

  10. Thompson GR, Duff IF, Robinson WD, et al. Long term uricosuric therapy in gout. Arthritis Rheum 1962; 5: 384–96

    Article  PubMed  CAS  Google Scholar 

  11. Bartels E, Matossian G. Gout: six-year follow-up on probenecid (Benemid) therapy. Arthritis Rheum 1959; 2: 193–202

    Article  PubMed  CAS  Google Scholar 

  12. Yü Ts-F, Gutman AB. Effect of allopurinol (4-hydroxypyrazolo(3,4-d)pyrimidine) on serum and urinary uric acid in primary and secondary gout. Am J Med 1964; 37: 885–98

    Article  Google Scholar 

  13. Lang F, Greger R, Oberleithner H, et al. Renal handling of urate in healthy man in hyperuricaemia and renal insufficiency: circadian fluctuation, effect of water diuresis and of uricosuric agents. Eur J Clin Invest 1980; 10: 285–92

    Article  PubMed  CAS  Google Scholar 

  14. Tjandramaga T, Cucinell S, Israili ZH, et al. Observations on the disposition of probenecid in patients receiving allopurinol. Pharmacol 1972; 8: 259–72

    Article  CAS  Google Scholar 

  15. Talbott JH. Treating gout: successful methods of prevention and control. Postgrad Med 1978; 63: 175–80

    PubMed  CAS  Google Scholar 

  16. Yamamoto T, Moriwaki Y, Takahashi S, et al. Effects of pyrazinamide, probenecid and benzbromarone on renal excretion of oxypurinol. Ann Rheum Dis 1991; 50: 631–3

    Article  PubMed  CAS  Google Scholar 

  17. Müller FO, Schall R, Groenewoud G, et al. The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout. Eur J Clin Pharmacol 1993; 44: 69–72

    Article  PubMed  Google Scholar 

  18. Mertz D, Eichorn R. Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol? Klin Wochenschr 1984; 62: 1170–2

    Article  PubMed  CAS  Google Scholar 

  19. Reinders M, van Roon E, Houtman P, et al. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clinical Rheumatology 2007; 26: 1459–65

    Article  PubMed  Google Scholar 

  20. Jansen T, Reinders M, van Roon E, et al. Benzbromarone withdrawn from the European market: another case of “absence of evidence is evidence of absence”?. Clin Exp Rheumatol 2004; 22: 651

    PubMed  Google Scholar 

  21. Arai M, Yokosuka O, Fujiwara K, et al. Fulminant hepatic failure associated with benzbromarone treatment: a case report. J Gastroenterol Hepatol 2002; 17: 625–6

    Article  PubMed  Google Scholar 

  22. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41

    Article  PubMed  CAS  Google Scholar 

  23. Turnheim K, Krivanek P, Oberbauer R. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. Br J Clin Pharmacol 1999; 48: 501–9

    Article  PubMed  CAS  Google Scholar 

  24. Emmerson B, Gordon R, Cross M, et al. Plasma oxipurinol concentrations during allopurinol therapy. Br J Rheumatol 1987; 26: 445–9

    Article  PubMed  CAS  Google Scholar 

  25. de Vries J, Voss A, Kutschker C, et al. Simultaneous determination of allopurinol and oxipurinol in human plasma and urine by high-performance liquid chromatography. Arzneim-Forsch/Drug Res 1993; 43: 1072–7075

    Google Scholar 

  26. Seki T, Sato N, Hasegawa T, et al. Nasal absorption of zidovudine and its transport to cerebrospinal fluid in rats. Biol Pharm Bull 1994; 17: 1135–7

    Article  PubMed  CAS  Google Scholar 

  27. Fossati P, Prencipe L, Berti G. Use of 3,5-dichloro-2-hydroxybenzenesulfonic acid/4-aminophenazone chromogenic system in direct enzymic assay of uric acid in serum and urine. Clin Chem 1980; 26: 227–31

    PubMed  CAS  Google Scholar 

  28. Higgens C, Scott J. The uricosuric action of azapropazone: dose-response and comparison with probenecid. Br J Clin Pharmac 1984; 18: 439–43

    Article  CAS  Google Scholar 

  29. Graham S, Day R, Wong H, et al. Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects. Br J Clin Pharmacol 1996; 41: 299–304

    Article  PubMed  CAS  Google Scholar 

  30. Garyfallos A, Magoula I, Tsapas G. Evaluation of the renal mechanisms for urate homeostasis in uremic patients by probenecid and pyrazinamide test. Nephron 1987; 46: 273–80

    Article  PubMed  CAS  Google Scholar 

  31. Elion GB, Yü TF, Gutman AB, et al. Renal clearance of oxipurinol, the chief metabolite of allopurinol. Am J Med 1968; 45: 69–77

    Article  PubMed  CAS  Google Scholar 

  32. Iwanaga T, Kobayashi D, Hirayama M, et al. Involvement of uric acid transporter in increase renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab Dispos 2005; 33: 1791–5

    PubMed  CAS  Google Scholar 

  33. Colin JN, Farinotti R, Fredj G, et al. Kinetics of allopurinol and oxipurinol after chronic oral administration: interaction with benzbromarone. Eur J Clin Pharmacol 1986; 31: 53–8

    Article  PubMed  CAS  Google Scholar 

  34. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature 2002; 417: 447–52

    PubMed  CAS  Google Scholar 

  35. Lartigue-Mattei C, Chabard J, Risori J, et al. Kinetics of allopurinol and its metabolite oxypurinol after oral administration of allopurinol alone or associated with benzbromarone in man: simultaneous assay of hypoxanthine and xanthine by gas chromatography-mass spectrometry. Fundam Clin Pharmacol 1991; 5: 621–33

    Article  PubMed  CAS  Google Scholar 

  36. Rüffer C, Zorn G, Henkel E, et al. Influence of benzbromarone on the pharmacokinetics and pharmacodynamics of oxipurinol. Arzneim-Forsch/Drug Res 1982; 32: 1149–52

    Google Scholar 

  37. Akkasilpa S, Osiri M, Deesomchok U, et al. The efficacy of combined low dose of allopurinol and benzbromarone compared to standard dose of allopurinol in hyperuricemia. J Med Assoc Thai 2004; 87: 1087–91

    PubMed  Google Scholar 

  38. Hanviadhanakul P, Akkasilpa S, Deesomchok U. Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients. J Med Assoc Thai 2002; 85: S40–S7

    Google Scholar 

  39. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia: a pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998; 57: 545–9

    Article  PubMed  CAS  Google Scholar 

  40. Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450–61

    Article  PubMed  CAS  Google Scholar 

  41. Rivera JV. Uricosuric effects of probenecid and zoxazolamine in gout: a comparative study. Arch Intern Med 1961; 108: 512–8

    Article  PubMed  CAS  Google Scholar 

  42. Gutman A, Yü T-F, Randolph V. Further observation on the uricosuric effects of probenecid (Benemid) in tophaceous gout. Trans Assoc Am Physicians 1954; 67: 250–60

    PubMed  CAS  Google Scholar 

  43. Bishop C, Rand R, Talbott JH. The effect of benemid (P-[DI-N-propylsulfamyl]-benzoic acid) on uric acid metabolism in one normal and one gouty subject. J Clin Invest 1951 Aug; 30: 889–95

    Article  PubMed  CAS  Google Scholar 

  44. Rodnan G, Robin J, Tolchin SF, et al. Allopurinol and gouty hyperuricemia: efficacy of a single daily dose. JAMA 1975; 231: 1143–7

    Article  PubMed  CAS  Google Scholar 

  45. Bianchi R, Vitali C, Clerico A, et al. Uric acid metabolism in normal subjects and in gouty patients by chromatographic measurement of 14C-uric acid in plasma and urine. Metabolism 1979; 28: 1105–13

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors acknowledge the coordinators and Dr W. Liauw of the St Vincent’s Hospital Clinical Trials Centre and the clinical staff and Dr John Ray of SydPath (St Vincent’s Hospital, Sydney, NSW, Australia) for their invaluable assistance. No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Richard O. Day.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stocker, S.L., Williams, K.M., McLachlan, A.J. et al. Pharmacokinetic and Pharmacodynamic Interaction between Allopurinol and Probenecid in Healthy Subjects. Clin Pharmacokinet 47, 111–118 (2008). https://doi.org/10.2165/00003088-200847020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200847020-00004

Keywords

Navigation